to their inherent complexity, hence require more comprehensive analytical and functional characterization during their discovery, development and manufacturing. Somatropin (i.e. recombinant human growth hormone, rhGH) modified with the chelating agent S-2-(4isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) allows the incorporation of radiometals for research and possible theranostic purposes. We previously demonstrated that this conjugation leads to multiple substitution degrees and positional isomers within the product. In vitro techniques at molecular and cellular level were now applied to assess their functional quality: (i) size exclusion chromatography (SEC) demonstrated functional complexation with human growth hormone binding protein (hGHBp) to the different NOTA-modified somatropins, as well as to gallium chelated NOTAfunctionalities (Ga-10:1 NOTA:somatropin); (ii) native MS offered in-depth information: a substitution degree up to four NOTAs was still functional; (iii) circular dichroism (CD) analysis confirmed the complexation of unmodified and NOTA-modified somatropin to hGHBp; and (iv) a hGHR bioassay demonstrated initiation of the signal transduction cascade, after binding of all investigated products to the receptor presented on cells with a similar potency (pEC 50 value between 9.53 and 9.78) and efficacy (E max values between 130 and 160%). We conclude that the NOTA-modified somatropins do not possess a significantly different in vitro functionality profile compared to unmodified somatropin. Techniques such as SEC, MS and CD, traditionally used in the physicochemical characterization of proteins, have a demonstrated potential use in the functionality evaluation not only in drug discovery and development but also in quality control settings.
INTRODUCTION
Protein biopharmaceuticals are an established class within the medicinal product landscape and their members include complex molecules such as hormones, cytokines, monoclonal antibodies (mAbs), fusion proteins and therapeutic enzymes [1] [2] [3] . Compared to small molecules, the protein biopharmaceuticals form a more complex product class inherent to (i) their size, e.g. mAbs are approximately 150 kDa consisting of different chains, and (ii) their chemical and/or enzymatic modifications/truncations originating from expression, manufacturing and/or storage 4, 5 . One cloned recombinant protein can thus lead to many variants that each contribute to the overall quality, safety and efficacy of the product. In comparison to the unmodified protein biopharmaceuticals, chemical modifications such as polyethylene glycol (PEG), bifunctional chelating agents (e.g. 1,4,7-triazacyclononane-1,4,7triacetic acid (NOTA)) and drug conjugations, render the protein additional functionalities.
These modifications can, for example, influence the protein efficacy and create opportunities to deliver a payload such as a radionuclide or cytotoxic drug 6 . These chemical modifications typically target different reactive amino acid residues throughout the protein sequence such as lysine and cysteine residues, leading to different substitution degrees and positional isomers within the product, hence introducing more heterogeneity to the product 7, 8 . Control of a specific conjugation site is usually impossible and conjugation at the target-binding interface can lead to unwanted or abolished interactions, as well as an altered pharmacokinetic profile 9, 10 .
The development of a heterogeneous active pharmaceutical ingredient (API) into a medicinal product requires more regulatory effort and a thorough chemical and functional characterization during development and manufacturing prior to clinical or commercial release. These requirements come along with the need for more advanced analytical tools and further investment in their development. Chromatographic, electrophoretic and mass 4 spectrometric approaches are traditionally applied for the physicochemical characterization (e.g. substitution degree, position isomers, oligomerization, molecular weight, etc.) [11] [12] [13] , while classical biochemical and cellular assays 14 as well as emerging techniques such as biosensors 15, 16 have been applied in the functional characterization. Nowadays, a combined approach within analytical techniques is made from solely physicochemical to a combined functional characterization.
Growth hormone (GH) is a key anabolic hormone, known to stimulate lipolysis during fasting 17, 18 , to regulate skeletal muscle metabolism 18, 19 and to have an important role in bone metabolism throughout life 20 . The last decades, the interest in the actions of GH and the GH receptor (GHR) in cancer progression is growing [21] [22] [23] [24] [25] [26] [27] [28] [29] . For example, a higher GHR expression was observed in prostate carcinoma 30 and breast cancer tissue 31 , as well as a higher GHR and GH expression in prostate cancer cell lines 32 and in large cell neuroendocrine carcinoma tissue 33 . The pleiotropic effects of GH are mediated after binding to a predimerized receptor presented at the cell surface of target cells, thereby forming a functional 2:1 GHR:GH complex and initiating the signal transduction cascade 19, 29, 34 .
Modification of biological substances with chelating agents (e.g. NOTA) allow the incorporation of radiometals for single-photon emission computed tomography/positron emission tomography (SPECT/PET)-research, diagnostic or therapeutic purposes. Such NOTA-somatropins have been previously developed and chemically characterized 8 . In this study, we evaluated the in vitro functional quality by means of traditional physicochemical techniques and cellular techniques. 5 
MATERIALS AND METHODS

Chemicals and materials
The S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) was purchased from Macrocyclics Inc. (Dallas, TX, USA). Zomacton ® 4 mg, (Ferring, somatropin Ph.Eur.) was obtained from the Ghent University Hospital (Ghent, Belgium) and human growth hormone binding protein (hGHBp) from MyBiosource (San Diego, USA). The purity quality evaluation, using SDS-PAGE, is represented in Supplementary information Figure S1 . PD-10 sephadex G-25M columns were acquired from GE healthcare (Diegem, Belgium). Water was purified in-house using an Arium Pro VF TOC purification system (Sartorius, Göttingen, Germany), yielding 18.2 MΩ*cm and ≤ 5 ppb TOC quality water. Other chemicals and solvents were purchased from Merck (Overijse, Belgium), Sigma Aldrich (Diegem, Belgium), Biosolve (Valkenswaard, The Netherlands) or Fischer Scientific (Erembodegem, Belgium), all high quality (>98% purity) and/or HPLC/MS grade. assay with JAK2 target was from DiscoverX (Fremont, USA). CD analysis was performed on a Jasco J-815 CD spectrometer (Tokyo, Japan).
Synthesis of NOTA-modified somatropin and complexation with gallium
The synthesis procedure of 1:1 NOTA:somatropin, 3:1 NOTA:somatropin and 10:1 NOTA:somatropin was previously detailed by Bracke et al. 8 and are the resulting products of respectively equimolar, three times and ten times molar excess of p-SCN-Bn-NOTA over conjugation and gallium chelation using trypsin and chymotrypsin peptide mapping was performed as previously described with analogous results 8 . 35 , assuming no changes in response factor after gallium chelation and NOTA-conjugation of somatropin:
Analytical size-exclusion chromatography
(1) The data between m/z 3000-4000 of the complex sample and complex standard were further analysed using a Python program. Data were smoothed using a moving average filter (301 points). The baseline was fitted in regions without protein signal with a quadratic function.
Native MS analysis
Peak deconvolution was performed on offset data (i.e. baseline subtracted) using the sum of exponential Gaussian peak algorithm, using the least-squares fitting technique. 
Circular dichroism analysis
In vitro GHR bio-assay
The PathHunter Cytosolic Tyrosine Kinase (CTK) Functional Assay (JAK2 target) was used for the profiling of NOTA-modified somatropins in agonist and antagonist format. The cells (U2OS cell background) were seeded in a total volume of 20 μL Cell Plating Reagent (i.e. 1%
Charcoal/Dextran-treated Fetal Bovine Serum) into 384-well microplates. For agonist determination, cells were incubated with sample to induce a response. An intermediate dilution of sample stocks was prepared to generate 5X sample in assay buffer (0.1% BSA in PBS). Five microliter of 5X sample was added to each well and incubated for three hours. In antagonist mode, cells were pre-incubated with sample for 60 min at 37°C, followed by hGH 9 agonist incubation for three hours (EC80 challenge; 0.012 µg/mL hGH). Assay signal was generated through a single addition of 12.5 or 15.0 μL (50% V/V) of PathHunter Detection reagent cocktail for agonist and antagonist assays respectively, followed by a one hour incubation at room temperature. The microplates were read and signals were generated with a For agonist mode assays, percentage activity was calculated using the following formula:
For antagonist mode assays, percentage inhibition was calculated using the following:
Data was further analyzed using non-linear regression (least square regression) to calculate the RC 50 (i.e. EC 50 or IC 50 ) and E max values (Prism 5 software, Graphpad, La Jolla, USA):
The pEC 50 (=logRC 50 in the above four parameters logistic sigmoid function) and E max values of the different compounds were compared using ANOVA (SPSS Statistics 24 software, New
York, USA).
RESULTS
Analytical size-exclusion chromatography
Analytical size exclusion chromatography (SEC) allows to evaluate the in vitro binding capacity of NOTA-modified somatropins to the soluble form and extracellular part of the human GHR, i.e. human growth hormone binding protein (hGHBp). The suitability of this method, known as the High Performance Receptor Binding Chromatography (HPRBC) method 35 , was confirmed using the unmodified somatropin standard and hGHBp on two SEC columns. Figures 1A and 1B show the stoichiometric analysis of hGHBp and somatropin, i.e. the concentration dependent dimerization mechanism with 2:1 hGHBp:somatropin complexes in excess hGHBp conditions and increasing 1:1 complexes in excess somatropin (analyte)
conditions. The 2:1 hGHBp:somatropin complex elutes first, followed by the 1:1 complex, somatropin and hGHBp. This ligand binding complexation is in agreement with the observations made in prior work 35, 38 . The hGHBp single protein chromatogram has several peaks indicating that the applied hGHBp consisted of a mixture of hGHBp-isoforms and impurities, including hGHBp oligomers (Supplementary information Figure S2) . Indeed, analysis on SDS-PAGE confirmed the presence of higher molecular weight substances (Supplementary information Figure S1 ).
All NOTA-modified somatropins were in a 2:1 complex when approximately 2-4.5 times molar excess of hGHBp was used (Figure 1C and 1D) , which demonstrated the bindingfunctionality and dimerization capacity of these NOTA-modified somatropins, as well as of the gallium chelated NOTA-modified somatropin towards hGHBp (Figure 1D) . A comparison of both silica based SEC columns is enclosed in Table S1 (supplementary information). They both have a different molecular weight range, but overlap in the region of interest (22 -78 kDa). The single proteins were also analysed ( Figure S3) . Each NOTAconjugation increases the molecular weight with 449.5 Da and, as previously observed, the substitution degree increases in the samples from 1:1 to 10:1 NOTA:somatropin 8 . We 
Native MS analysis of protein complexes
Confirmation and more in depth exploration of the SEC results, i.e. interrogation of the different product species (somatropins containing one, two or more NOTA-substitutions) for hGHBp-binding, was done by native MS. Native MS, also referred to as non-denaturing MS, allows the detection of the different substitution species-hGHBp-complexes in a single mass spectrum under non-denaturing conditions (i.e. typically volatile solutions such as ammonium acetate with reduced formation of adducts in the gas phase 39 ).
In general, the observed percentage substitution degree within the NOTA-modified somatropin samples (Figure 2E and Figure S4 ) are in agreement with previously reported data 8 . The spectra of the standard and sample complex solutions are given in Figure 2 . In the standard complex, ions corresponding to 1:1 (Figure 2A) semi-quantitative substitution degree species distribution in the single protein analyte samples (Figure 2E) suggests a similar distribution within the hGHBp:analyte complexes ( Figure   2F ). There were no free hGHBp ions detected in the complex samples, indicating the hGHBpbinding functionality of the different species within the samples. (F) Species distribution analysis within the analyte:hGHBp complex (z=15); analytes are shown on the x-axis.
Circular dichroism analysis
CD was used to additionally confirm the (modified) somotropin-hGHBp complex formation.
For proteins, the experimentally measured difference in left-and right-handed circularly polarized light in the far UV (below 250nm) is mainly due to the peptide bone (amide chromophore), reflecting the secondary structure of the protein. Ligand-binding interactions can be measured by CD due to the change in the secondary structure of one or both ligands upon interactions and hence a difference in CD spectrum. Hence, due to the additive properties of the UV-CD response [40] [41] , the comparison between the sum of the 2 individual spectra (i.e. the calculated, addition spectrum) with the experimentally obtained complexanalytes will demonstrate an interaction: if the experimentally observed and simulated-sum spectra are identical, there is no detectable interaction, whereas if the spectra are different, a binding interaction unambiguously took place. In Figure 3A and 3C, the result confirms our hypothesis, where the difference in 185-250nm range was observed indicating the interaction between unmodified somatropin and hGHBp. Similar spectral differences were found for the modified 10:1 NOTA:somatropin (Figures 3B and 3D) , indicating that both molecules show similar secondary structure change upon binding to hGHBp.
15 Figure 3 . CD spectra of (NOTA-modified) somatropin and hGHBp (n=2). (A) spectra of somatropin as analyte;
(B) spectra of 10:1 NOTA:somatropin as analyte; (C) difference spectra with somatropin as analyte; (D) difference spectra with 10:1 NOTA:somatropin as analyte.
In vitro GHR bio-assay
The functional quality of NOTA-modified somatropin for binding to the full length human GHR and activation/inhibition of the signal transduction cascade was evaluated using a PathHunter Cytosolic Tyrosine Kinase (CTK) functional GHR bioassay. This bioassay involves the intracellular JAK2 target, because this JAK2 pathway is the classical route of GHR signaling 42 .
An overview of the results is given in Figure 4 and Table 1 . 
DISCUSSION
The thorough regulatory requirements for biopharmaceuticals have shifted the use of techniques and methods that were previously solely used for physicochemical characterization to a combined functionality characterization. For example, in the European Pharmacopoeia, SEC is generally used in the test for related substances of higher molecular mass in the protein monographs (e.g. Ph. Eur.8.8: 01/2008:0951 43 ). Also MS is generally used for peptide mapping purposes or direct analysis of proteins, allowing identification of the substitution degree of the conjugate/post-translational modification, as well as identification of the modification hot spot 8, 11 . By the inclusion of a receptor or target within the sample, the Native MS is nowadays an established technique during the drug discovery phases, such as during the chemical characterization of modified proteins 46 , the characterization of proteinmetal complexes destined for either diagnostic or therapeutic purposes 47 , and, during the investigation of interactions between protein drugs with their therapeutic targets/physiological partners, including unmodified proteins and their modified versions [48] [49] [50] [51] . In this study, the different substitution-degree species within the protein product were functionally evaluated for hGHBp binding, thereby complementing the information provided by SEC/HPRBC.
Confirmation was obtained by the conformation-sensitive UV-CD result under physiological
conditions.
In addition to these traditional techniques, also new emerging tools such as biosensors are making an evolution from lab bench equipment to work horses in the industrial settings. For example, we demonstrated that the binding kinetics of these NOTA-modified somatropins were not significantly different from somatropin using a SAW biosensor technique with an antibody ligand (K D between 15 and 19 nM) 52 .
Finally, we used a classical cell assay with full length receptor. We observed a similar potency and efficacy of all investigated somatropin products, meaning that the NOTAmodified somatropins are functional in a biological context and thus confirm our previous results from HPRBC/SEC, native MS and CD. The NOTA-conjugation hotspot within somatropin is K70, followed by K158, and with a lower reactivity K140 and K172 8 . Based on the crystal structure of hGHBp 2 :hGH (Figure 5) , K172 is pointed to the receptor binding site I and has the potential to sterically hinder the receptor after modification with NOTA.
Using mutational studies, Cunningham et al. demonstrated that K172 is a binding hotspot within site I 44 . A reduced affinity for GHR was also observed after conjugation of K172 with PEG5000 53 . Compared to PEG with an average molecular weight of 5000 Da, the NOTA addition here is much smaller (449.5 Da). The other identified lysine residues prone to conjugation show enough conformational freedom to have no direct interference with receptor binding. Our results show that all investigated products, including species with a substitution degree of four NOTAs, can bind to the receptor and hence display receptor bindingfunctionality.
Thus, we have investigated the in vitro functionality of the NOTA-modified somatropins on two levels: (i) on molecular level using hGHBp (HPRBC/SEC, native MS and CD), with emphasis on the switch from classical physicochemical characterization techniques to more 19 functionality characterization, and (ii) on cellular level by the detection of activation/inhibition of the GHR-signal transduction cascade in a biological context. 
CONCLUSION
HPRBC/SEC and native MS demonstrated that all different NOTA-substituted somatropins, including gallium chelated NOTA-moieties, were able to bind the hGHBp. Native MS showed binding of the products with a substitution degree of 4 NOTAs. The hGHR bioassay using the JAK2 target, demonstrated a similar potency (pEC 50 values ranged 9.53 between 20 9.78) and efficacy (E max values ranged 130 between 160) of all investigated compounds (i.e. somatropin and the NOTA-modified samples). The use of molecular techniques HPRBC/SEC, native MS and CD, as well as a cell assay complemented the obtained results to evaluate the functional quality of the NOTA-modified somatropins. We demonstrated that techniques such as SEC, MS and CD, classically used in the physicochemical characterization of proteins, have a potential use not only in the functionality evaluation in drug discovery and development but also in quality control settings.
